Clinical Cancer Research, Vol 4, Issue 10 2313-2320, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects

MP Goren, JM Houle, DA Bush, JT Li, CE Newman and WP Brade
Department of Pathology and Laboratory Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.

Although mesna has been used for more than a decade to reduce the incidence of hemorrhagic cystitis induced by ifosfamide and cyclophosphamide, the disposition of i.v. and oral mesna has not been adequately described. To obtain accurate bioavailability data for the design of mesna regimens, we developed procedures to preserve and measure mesna and dimesna in the blood and urine and studied 25 volunteer subjects who received single doses of i.v. mesna and four different formulations of oral mesna in a five-way randomized crossover study. The dose-adjusted area under the blood concentration-time curve showed no difference in bioavailability for i.v. and oral mesna; however, the maximum mesna concentration after oral doses was 16% of that estimated for i.v. doses. The short initial half-life of i.v. mesna indicated that mesna was rapidly cleared; however, the blood concentrations of mesna uniformly exceeded those of dimesna after oral as well as i.v. doses, which suggested that reduced mesna and oxidized mesna disulfide are in equilibrium. The ratio of mesna:dimesna was higher in protein-free plasma than it was in the urine, which suggested that most urinary mesna is produced by glomerular filtration of mesna rather than by renal tubular reduction of dimesna. The sum of mesna and dimesna excretion after the i.v. doses (73% of the dose) and the four oral formulations (68-73%) showed no difference in urinary bioavailability, consistent with the blood data. However, the urinary bioavailability of the therapeutically active free-thiol mesna was greater after i.v. doses (40% of the dose) than it was after oral doses (31-33%). The ratio of oral:i.v. mesna excretion ranged from 0.52-1.23 (mean, 0.82) among the 24 subjects. Urinary mesna concentrations exceeded 50 microM in all subjects for up to 12 h after oral doses as compared to 4 h after i.v. doses. About 90% of this mesna was excreted by hour 2 after i.v. doses and by hour 9 after oral doses. The mean maximum concentration of mesna in blood and excretion into urine were both 2.6 h after dosing. The oral formulations thus showed sustained urinary excretion, and their urinary bioavailability approached that of i.v. mesna.

This article has been cited by other articles:

				J. R. Mace, M. L. Keohan, H. Bernardy, K. Junge, G. Niebch, P. Romeis, A. Thoma, T. Wagner, U. Mueller, G. Demetri, et al. Crossover Randomized Comparison of Intravenous versus Intravenous/Oral Mesna in Soft Tissue Sarcoma Treated with High-Dose Ifosfamide Clin. Cancer Res., December 1, 2003; 9(16): 5829 - 5834. [Abstract] [Full Text] [PDF]

				M. H. Cohen, R. Dagher, D. J. Griebel, A. Ibrahim, A. Martin, N. S. Scher, G. H. Sokol, G. A. Williams, and R. Pazdur U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid Oncologist, October 1, 2002; 7(5): 393 - 400. [Abstract] [Full Text] [PDF]